中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

32 records (took 0.021 seconds)

    Crystalline forms of a Bruton's tyrosine kinase inhibitor
    1.
    发明专利
    Crystalline forms of a Bruton's tyrosine kinase inhibitor 未知

    公开(公告)号：AU2020239751B2

    公开(公告)日：2022-10-27

    申请号：AU2020239751

    申请日：2020-09-24

    Applicant: PHARMACYCLICS LLC

    Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

    IPC: A61K47/38 ,  A61K9/48 ,  A61K47/30 ,  A61P29/00 ,  A61P35/00

    Abstract: CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    Crystalline forms of a Bruton's tyrosine kinase inhibitor
    2.
    发明专利
    Crystalline forms of a Bruton's tyrosine kinase inhibitor 未知

    公开(公告)号：AU2018211201A1

    公开(公告)日：2018-08-16

    申请号：AU2018211201

    申请日：2018-07-31

    Applicant: PHARMACYCLICS LLC

    Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

    IPC: A61K47/38 ,  A61K9/48 ,  A61K47/30 ,  A61P29/00 ,  A61P35/00

    Abstract: CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)prop-2-en- 1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (20992107_1):GGG

    Crystalline forms of a Bruton's tyrosine kinase inhibitor
    3.
    发明专利
    Crystalline forms of a Bruton's tyrosine kinase inhibitor 未知

    公开(公告)号：AU2013271918C1

    公开(公告)日：2017-02-09

    申请号：AU2013271918

    申请日：2013-06-03

    Applicant: PHARMACYCLICS LLC

    Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

    IPC: A61K47/38 ,  A61K9/48 ,  A61K47/30 ,  A61P29/00 ,  A61P35/00

    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    5.
    发明专利
    CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR 未知

    公开(公告)号：ZA202105175B

    公开(公告)日：2022-07-27

    申请号：ZA202105175

    申请日：2021-07-22

    Applicant: PHARMACYCLICS LLC

    Inventor： PURRO NORBERT ,  SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D

    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON
    6.
    发明专利
    FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON 未知

    公开(公告)号：AR118108A2

    公开(公告)日：2021-09-15

    申请号：ARP200100425

    申请日：2020-02-14

    Applicant: PHARMACYCLICS LLC

    Inventor： WIRTH DAVID D ,  GOLDMAN ERICK ,  SMYTH MARK ,  PURRO NORBERT

    IPC: A61K31/519 ,  A61K9/48 ,  A61K47/30 ,  A61K47/38 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  C07D487/04

    Abstract: Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias. Reivindicación 1: Una preparación farmacéutica para administración oral caracterizada porque comprende: (a) más o menos 40 a más o menos 200 mgs de 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona; (b) más o menos 40% en peso a más o menos 50% en peso de un diluyente; (c) más o menos 3% en peso a más o menos 10% en peso de un agente desintegrador; (d) más o menos 2% en peso a más o menos 7% en peso de un agente de actividad superficial; y (e) más o menos 0,2% en peso a más o menos 1,0% en peso de un lubricante. Reivindicación 2: La preparación farmacéutica, de acuerdo con la reivindicación 1, caracterizada porque el diluyente está seleccionado a partir del grupo que consiste de lactosa, sucrosa, dextrosa, dextratos, maltodextrin, manitol, xilitol, sorbitol, ciclodextrinas, fosfato de calcio, sulfato de calcio, almidones, almidones modificados, celulosa microcristalina, microcelulosa, etc. Reivindicación 3: La preparación farmacéutica, de acuerdo con la reivindicación 2, caracterizada porque el diluyente es una celulosa microcristalina. Reivindicación 11: La preparación farmacéutica, de acuerdo con cualesquiera reivindicaciones 1 - 10, caracterizada porque la forma de dosificación es una cápsula de gelatina dura.

    FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON
    7.
    发明专利
    FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON 未知

    公开(公告)号：ECSP19015794A

    公开(公告)日：2019-03-29

    申请号：ECDI201915794

    申请日：2019-03-06

    Applicant: PHARMACYCLICS LLC

    Inventor： WIRTH DAVID ,  PURRO NORBERT ,  GOLDMAN ERICK ,  SMYTH MARK

    IPC: A61K47/38 ,  A61K9/48 ,  A61K47/30 ,  A61P29/00 ,  A61P35/00

    Abstract: Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias.

    Crystalline forms of a Bruton's tyrosine kinase inhibitor
    8.
    发明专利
    Crystalline forms of a Bruton's tyrosine kinase inhibitor 未知

    公开(公告)号：AU2018211216A1

    公开(公告)日：2018-08-16

    申请号：AU2018211216

    申请日：2018-07-31

    Applicant: PHARMACYCLICS LLC

    Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

    IPC: A61K47/38 ,  A61K9/48 ,  A61K47/30 ,  A61P29/00 ,  A61P35/00

    Abstract: CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)prop-2-en- 1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (20992107_1):GGG

    КРИСТАЛІЧНА ФОРМА ІНГІБІТОРУ ТИРОЗИНКІНАЗИ БРУТОНА
    9.
    发明专利
    КРИСТАЛІЧНА ФОРМА ІНГІБІТОРУ ТИРОЗИНКІНАЗИ БРУТОНА 未知

    公开(公告)号：UA114421C2

    公开(公告)日：2017-06-12

    申请号：UAA201414091

    申请日：2013-06-03

    Applicant: PHARMACYCLICS LLC

    Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

    IPC: A61K9/48 ,  A61K47/38 ,  A61K47/30 ,  A61P29/00 ,  A61P35/00

    Abstract: УданійзаявцірозкриваєтьсяінгібітортирозинкіназиБрутона (Btk) 1-((R)-3-(4-аміно-3-(4-феноксифеніл)-1H-піразоло[3,4-d]піримідин-1-іл)піпередин-1-іл)проп-2-ен-1-он, включаючийогокристалічніформи, сольватитафармацевтичноприйнятнісолі. Такожрозкриваютьсяфармацевтичнікомпозиції, яківключаютьінгібітор Btk, іспособизастосуванняінгібітору Btk, самостійноабов комбінаціїз іншимитерапевтичнимиагентами, длялікуванняаутоімуннихзахворюваньабопатологічнихстанів, гетероімуннихзахворюваньабопатологічнихстанів, раку, включаючилімфомутазапальнізахворюванняабопатологічністани.

    Crystalline forms of a Bruton's tyrosine kinase inhibitor
    10.
    发明专利
    Crystalline forms of a Bruton's tyrosine kinase inhibitor 未知

    公开(公告)号：AU2016250445A1

    公开(公告)日：2016-11-17

    申请号：AU2016250445

    申请日：2016-10-28

    Applicant: PHARMACYCLICS LLC

    Inventor： SMYTH MARK ,  GOLDMAN ERICK ,  WIRTH DAVID D ,  PURRO NORBERT

    IPC: A61K47/38 ,  A61K9/48 ,  A61K47/30 ,  A61P29/00 ,  A61P35/00

    Abstract: CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1 -yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Patent Agency Ranking